BidaskClub upgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a strong sell rating to a sell rating in a report published on Monday, February 5th.
A number of other research firms have also recently commented on ACHN. Leerink Swann reiterated a buy rating and set a $5.00 price objective on shares of Achillion Pharmaceuticals in a research report on Monday, December 11th. Zacks Investment Research cut Achillion Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $4.89.
Shares of Achillion Pharmaceuticals (NASDAQ ACHN) opened at $3.01 on Monday. Achillion Pharmaceuticals has a fifty-two week low of $2.58 and a fifty-two week high of $5.66. The company has a market capitalization of $410.82, a price-to-earnings ratio of -6.27 and a beta of 1.32.
Several hedge funds and other institutional investors have recently made changes to their positions in ACHN. TIAA CREF Investment Management LLC raised its position in Achillion Pharmaceuticals by 13.2% during the fourth quarter. TIAA CREF Investment Management LLC now owns 363,571 shares of the biopharmaceutical company’s stock valued at $1,047,000 after buying an additional 42,358 shares during the period. Teachers Advisors LLC increased its position in Achillion Pharmaceuticals by 3.9% in the 4th quarter. Teachers Advisors LLC now owns 1,552,264 shares of the biopharmaceutical company’s stock worth $4,471,000 after purchasing an additional 57,782 shares during the last quarter. Sarissa Capital Management LP increased its position in Achillion Pharmaceuticals by 17.0% in the 4th quarter. Sarissa Capital Management LP now owns 2,500,000 shares of the biopharmaceutical company’s stock worth $7,200,000 after purchasing an additional 363,200 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Achillion Pharmaceuticals in the 4th quarter worth about $2,880,000. Finally, Two Sigma Investments LP acquired a new position in Achillion Pharmaceuticals in the 4th quarter worth about $3,190,000. 76.81% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://weekherald.com/2018/02/15/achillion-pharmaceuticals-achn-lifted-to-sell-at-bidaskclub.html.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.